Acorda Therapeutics (ACOR)
Acorda Therapeutics (ACOR - Analyst Report) is one of the more interesting biotechnology companies under our coverage. The company's key pipeline drug, Fampridine-SR, is currently under U.S. FDA review, with a decision expected in late January 2010.
Outside the U.S., Acorda has partnered with Biogen Idec under very favorable terms. Fampridine-SR has blockbuster potential worldwide in our view. Plus, the company is extremely well-capitalized with over $290 million in cash, and management has commercial experience with current approved product Zanaflex.
These are among the best fundamentals in all of biotech. We reiterate our Outperform rating on the stock.
Acorda Therapeutics (ACOR) : FULL ANALYST REPORT
|
|
|
|
Share |
RSS |
Rate Pos |
Rate Neg |
Comment |
|
|
||||||
- Free Four Zacks #1 Rank "Strong Buy" Stocks
- Free Timely Market Commentary
- Free Wealth Management Tips
- Free Profitable Strategy Screens
- Free Bull and Bear Stocks of the Day
Loading Stories...Most Popular on Zacks.com
More Zacks Resources
More Zacks Links
| Market Summary | Mar 11, 2010 07:23 am ET |


Sponsored Links 
0.00 %
[CLICK TO CLOSE X]